Chimerix (CMRX)
(Delayed Data from NSDQ)
$1.00 USD
-0.05 (-4.76%)
Updated May 14, 2024 04:00 PM ET
After-Market: $1.00 0.00 (0.00%) 7:58 PM ET
4-Sell of 5 4
C Value F Growth F Momentum F VGM
Brokerage Reports
Chimerix, Inc. [CMRX]
Reports for Purchase
Showing records 1 - 20 ( 114 total )
Company: Chimerix, Inc.
Industry: Medical - Products
Company: Chimerix, Inc.
Industry: Medical - Products
Company: Chimerix, Inc.
Industry: Medical - Products
Company: Chimerix, Inc.
Industry: Medical - Products
4Q23 Results; Interim OS Data From the Phase 3 ACTION Study Expected in 2025
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: Chimerix, Inc.
Industry: Medical - Products
Company: Chimerix, Inc.
Industry: Medical - Products
Company: Chimerix, Inc.
Industry: Medical - Products
3Q23 Results; Phase 3 ONC201 Data Expected 1H25; Phase 1 ONC206 Safety Data Projected For 1H24
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: Chimerix, Inc.
Industry: Medical - Products
Company: Chimerix, Inc.
Industry: Medical - Products
Company: Chimerix, Inc.
Industry: Medical - Products
Positive Median Overall Survival Results For ONC201 Published
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: Chimerix, Inc.
Industry: Medical - Products
Company: Chimerix, Inc.
Industry: Medical - Products
2Q23 Results; Phase 3 ACTION Study Sites Activating at Good Pace; ONC206 Dose Escalation Expected to Complete 1H24
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: Chimerix, Inc.
Industry: Medical - Products
Company: Chimerix, Inc.
Industry: Medical - Products
2Q23 Results; Steadily Advancing Oncology Portfolio Lays Groundwork For Multiple Catalysts in 2H23
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Chimerix, Inc.
Industry: Medical - Products
Initial Takeaways for Days 1-3 of ASCO 2023; Roundup for Covered Companies
Provider: Wedbush Securities Inc.
Analyst: NIERENGARTEN D
Company: Chimerix, Inc.
Industry: Medical - Products
Company: Chimerix, Inc.
Industry: Medical - Products
1Q23 Results; Phase 3 ACTION Study Efficacy Data in Early-2025
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: Chimerix, Inc.
Industry: Medical - Products
Company: Chimerix, Inc.
Industry: Medical - Products
Biotechnology- Roundup for 2023 AACR Meeting
Provider: Wedbush Securities Inc.
Analyst: NIERENGARTEN D
Company: Chimerix, Inc.
Industry: Medical - Products
Biotechnology -AACR 2023 Abstract Roundup For Covered Companies
Provider: Wedbush Securities Inc.
Analyst: NIERENGARTEN D